<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>LEVOBUNOLOL HYDROCHLORIDE- levobunolol hydrochloride solution/ drops </strong><br>Bausch &amp; Lomb Incorporated<br></p></div>
<h1><span class="Bold">Levobunolol Hydrochloride Ophthalmic Solution USP (Sterile)</span></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_436e1dd1-05a5-48c4-b684-615a4dd09cf0"></a><a name="section-1"></a><p></p>
<p class="First"> <span class="Bold">Rx only</span></p>
<p><span class="Bold">FOR USE IN THE EYES ONLY</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_f931274c-222e-4448-a91f-209168c96776"></a><a name="section-2"></a><p></p>
<h1>Description</h1>
<p class="First">Levobunolol Hydrochloride Ophthalmic Solution USP is a noncardioselective beta-adrenoceptor blocking agent for ophthalmic use.</p>
<p>Levobunolol hydrochloride is represented by the following structural formula:</p>
<div class="Figure">
<a name="id431"></a><img alt="Levobunolol Hydrochloride (Structural formula)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5ab1efbe-530b-4787-b40a-c7dbf18161e1&amp;name=371d1b92-5189-42bb-806f-6021eef34655-01.jpg">
</div>
<p>C<span class="Sub">17</span>H<span class="Sub">25</span>NO<span class="Sub">3</span>•HCl</p>
<p>Mol. Wt. 327.85</p>
<p><span class="Bold">Chemical Name: </span>(-)-5-[3-(tert-Butylamino)-2-hydroxypropoxy]-3,4-dihydro-1(2H)-naphthalenone hydrochloride.</p>
<p><span class="Bold">Each mL of 0.25% and 0.5% contains:</span></p>
<p>ACTIVE: Levobunolol Hydrochloride 2.5 mg (0.25%) and 5 mg (0.5%); INACTIVES: Polyvinyl Alcohol 1.4%, Sodium Chloride, Dibasic Sodium Phosphate, Edetate Disodium, Sodium Metabisulfite, Monobasic Potassium Phosphate, and Purified Water. Hydrochloric Acid and/or Sodium Hydroxide may be added to adjust pH (5.5 - 7.5); PRESERVATIVE ADDED: Benzalkonium Chloride (0.004%).</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_69159642-5603-4d91-b4cf-1421e5ad6a1e"></a><a name="section-3"></a><p></p>
<h1>Clinical Pharmacology</h1>
<p class="First">Levobunolol hydrochloride is greater than 60 times more potent than its dextro isomer in its beta-blocking activity, yet equipotent in its potential for direct myocardial <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>. Accordingly, the levo isomer, levobunolol hydrochloride, is used. Levobunolol hydrochloride does not have significant local anesthetic (membrane-stabilizing) or intrinsic sympathomimetic activity.</p>
<p>Beta-adrenergic receptor blockade reduces <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> in both healthy subjects and patients with heart disease. In patients with severe impairment of myocardial function, beta-adrenergic receptor blockade may inhibit the stimulatory effect of the sympathetic nervous system necessary to maintain adequate cardiac function.</p>
<p>Beta-adrenergic receptor blockade in the bronchi and bronchioles results in increased airway resistance from unopposed parasympathetic activity. Such an effect in patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or other bronchospastic conditions is potentially dangerous.</p>
<p>Levobunolol has been shown to be an active agent in lowering elevated as well as normal intraocular pressure (IOP) whether or not accompanied by <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>. Elevated IOP presents a major risk factor in glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic <span class="product-label-link" type="condition" conceptid="381732" conceptname="Nerve injury">nerve damage</span> and visual field loss.</p>
<p>The onset of action with one drop of levobunolol can be detected within one hour after treatment, with maximum effect seen between 2 and 6 hours.</p>
<p>A significant decrease in IOP can be maintained for up to 24 hours following a single dose.</p>
<p>In two separate, controlled studies (one three month and one up to 12 months duration) levobunolol hydrochloride ophthalmic solution 0.25% b.i.d. controlled the IOP of approximately 64% and 70% of the subjects. The overall mean decrease from baseline was 5.4 mm Hg and 5.1 mm Hg respectively. In an open-label study levobunolol hydrochloride ophthalmic solution 0.25% q.d. controlled the IOP of 72% of the subjects while achieving an overall mean decrease of 5.9 mm Hg.</p>
<p>In controlled clinical studies of approximately two years duration, intraocular pressure was well-controlled in approximately 80% of subjects treated with levobunolol hydrochloride ophthalmic solution 0.5% b.i.d. The mean IOP decrease from baseline was between 6.87 mm Hg and 7.81 mm Hg. No significant effects on pupil size, tear production or corneal sensitivity were observed. Levobunolol hydrochloride at the concentrations tested, when applied topically, decreased heart rate and blood pressure in some patients. The IOP-lowering effect of levobunolol was well maintained over the course of these studies.</p>
<p>In a three month clinical study, a single daily application of levobunolol hydrochloride ophthalmic solution 0.5% controlled the IOP of 72% of subjects achieving an overall mean decrease in IOP of 7.0 mm Hg.</p>
<p>The primary mechanism of the ocular hypotensive action of levobunolol hydrochloride in reducing IOP is most likely a decrease in aqueous humor production. Levobunolol reduces IOP with little or no effect on pupil size or accommodation in contrast to the <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span> which cholinergic agents are known to produce. The <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span> and <span class="product-label-link" type="condition" conceptid="374037" conceptname="Night blindness">night blindness</span> often associated with miotics would not be expected and have not been reported with the use of levobunolol. This is particularly important in <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> patients with central lens opacities who would experience decreased visual acuity with pupillary constriction.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_f94476e5-25e4-44bd-b414-6ee8071dab46"></a><a name="section-4"></a><p></p>
<h1>Indications and Usage</h1>
<p class="First">Levobunolol Hydrochloride Ophthalmic Solution has been shown to be effective in lowering intraocular pressure and may be used in patients with chronic open-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> or <span class="product-label-link" type="condition" conceptid="381290" conceptname="Ocular hypertension">ocular hypertension</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_16ca764a-4c96-4606-a284-b3a9f2cfb67d"></a><a name="section-5"></a><p></p>
<h1>Contraindications</h1>
<p class="First">Levobunolol Hydrochloride Ophthalmic Solution is contraindicated in those individuals with bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or with a history of bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, or severe <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span> (see <a href="#i4i_warnings_id_396d4f4b-40b7-44c3-8d75-e5ae839028f3">WARNINGS</a>); <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">sinus bradycardia</span>; second and third degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">atrioventricular block</span>; overt <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> (see <a href="#i4i_warnings_id_396d4f4b-40b7-44c3-8d75-e5ae839028f3">WARNINGS</a>); <span class="product-label-link" type="condition" conceptid="198571" conceptname="Cardiogenic shock">cardiogenic shock</span>; or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any component of these products.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_396d4f4b-40b7-44c3-8d75-e5ae839028f3"></a><a name="section-6"></a><p></p>
<h1>Warnings</h1>
<p class="First">As with other topically applied ophthalmic drugs, levobunolol may be absorbed systemically. The same adverse reactions found with systemic administration of beta-adrenergic blocking agents may occur with topical administration. For example, severe respiratory reactions and cardiac reactions, including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> in patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, and rarely <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in association with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, have been reported with topical application of beta-adrenergic blocking agents (see <a href="#i4i_contraindications_id_16ca764a-4c96-4606-a284-b3a9f2cfb67d">CONTRAINDICATIONS</a>). </p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_391ac847-6cdb-4656-9cd6-645b832191f0"></a><a name="section-6.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span></h2>
<p class="First">Sympathetic stimulation may be essential for support of the circulation in individuals with diminished myocardial contractility, and its inhibition by beta-adrenergic receptor blockade may precipitate more severe failure.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_219c2a0a-4259-46ed-9172-fe9225fcb469"></a><a name="section-6.2"></a><p></p>
<h2>In Patients Without a History of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span></h2>
<p class="First">Continued <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of the myocardium with beta-blocking agents over a period of time can, in some cases, lead to <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>. At the first sign or symptom of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, levobunolol should be discontinued.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c30028fd-871c-45e6-bffb-be08df9962e0"></a><a name="section-6.3"></a><p></p>
<h2>Obstructive Pulmonary Disease: </h2>
<p class="First">PATIENTS WITH <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">CHRONIC OBSTRUCTIVE PULMONARY DISEASE</span> (e.g. <span class="product-label-link" type="condition" conceptid="255841" conceptname="Chronic bronchitis">CHRONIC BRONCHITIS</span>, <span class="product-label-link" type="condition" conceptid="4169883" conceptname="Emphysema">EMPHYSEMA</span>) OF MILD OR MODERATE SEVERITY, BRONCHOSPASTIC DISEASE OR A HISTORY OF BRONCHOSPASTIC DISEASE (OTHER THAN BRONCHIAL <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">ASTHMA</span> OR A HISTORY OF BRONCHIAL <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">ASTHMA</span>, IN WHICH LEVOBUNOLOL IS CONTRAINDICATED, See CONTRAINDICATIONS), SHOULD IN GENERAL NOT RECEIVE BETA BLOCKERS, INCLUDING LEVOBUNOLOL. However, if levobunolol is deemed necessary in such patients, then it should be administered cautiously since it may block bronchodilation produced by endogenous and exogenous catecholamine stimulation of beta<span class="Sub">2</span> receptors.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_294c632f-559a-46bf-be5c-10f618ec05b3"></a><a name="section-6.4"></a><p></p>
<h2>Major Surgery</h2>
<p class="First">The necessity or desirability of withdrawal of beta-adrenergic blocking agents prior to major surgery is controversial. Beta-adrenergic receptor blockade impairs the ability of the heart to respond to beta-adrenergic mediated reflex stimuli. This may augment the risk of general anesthesia in surgical procedures. Some patients receiving beta-adrenergic receptor blocking agents have been subject to protracted severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> during anesthesia. Difficulty in restarting and maintaining the heartbeat has also been reported. For these reasons, in patients undergoing elective surgery, gradual withdrawal of beta-adrenergic receptor blocking agents may be appropriate. If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of such agonists as isoproterenol, dopamine, dobutamine or levaterenol (see <a href="#i4i_overdosage_id_aaa15869-04b0-4793-b903-3f1fe8eb84a1">OVERDOSAGE</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e3fbd2f9-267c-44b7-b80a-70ae941a728c"></a><a name="section-6.5"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus</h2>
<p class="First">Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> or to diabetic patients (especially those with labile <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>) who are receiving insulin or oral hypoglycemic agents. Beta-adrenergic receptor blocking agents may mask the signs and symptoms of acute <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_301c5b23-3138-47b9-a1d5-0b755601b6a9"></a><a name="section-6.6"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="138387" conceptname="Thyrotoxicosis">Thyrotoxicosis</span></h2>
<p class="First">Beta-adrenergic blocking agents may mask certain clinical signs (e.g. <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>) of <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>. Patients suspected of developing <span class="product-label-link" type="condition" conceptid="138387" conceptname="Thyrotoxicosis">thyrotoxicosis</span> should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blocking agents, which might precipitate a <span class="product-label-link" type="condition" conceptid="133436" conceptname="Thyrotoxic crisis">thyroid storm</span>.</p>
<p>These products contain sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> than in non-<span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> people.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8122a100-22ec-4dd8-84ed-141720a7db20"></a><a name="section-7"></a><p></p>
<h1>Precautions</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_b040b0ad-53d2-4893-a258-1f24dc663e5c"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">Levobunolol should be used with caution in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to other beta-adrenoceptor blocking agents. Use with caution in patients with known diminished pulmonary function.</p>
<p>Levobunolol should be used with caution in patients who are receiving a beta-adrenergic blocking agent orally, because of the potential for additive effects on systemic beta-blockade or on intraocular pressure. Patients should not typically use two or more topical ophthalmic beta-adrenergic blocking agents simultaneously.</p>
<p>Because of the potential effects of beta-adrenergic blocking agents on blood pressure and pulse rates, these medications must be used cautiously in patients with cerebrovascular insufficiency. Should signs or symptoms develop that suggest reduced cerebral blood flow while using levobunolol, alternative therapy should be considered.</p>
<p>In patients with angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, the immediate objective of treatment is to reopen the angle. This requires, in most cases, constricting the pupil with a miotic. Levobunolol Hydrochloride Ophthalmic Solution has little or no effect on the pupil. When levobunolol is used to reduce elevated intraocular pressure in angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, it should be followed with a miotic and not alone.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e2c7e640-a80e-4756-8164-0fa4d504c462"></a><a name="section-7.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">Muscle Weakness</span>:</h2>
<p class="First">Beta-adrenergic blockade has been reported to potentiate <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> consistent with certain myasthenic symptoms (e.g., <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="373194" conceptname="Paralytic ptosis">ptosis</span>, and generalized <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>).</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_b874350d-1aa0-4c4d-9d83-a8e12558ea40"></a><a name="section-7.3"></a><p></p>
<h2>Drug interactions</h2>
<p class="First">Although levobunolol used alone has little or no effect on pupil size, <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span> resulting from concomitant therapy with levobunolol and epinephrine may occur.</p>
<p>Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and/or marked <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, which may produce <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, or <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>. Patients receiving beta-adrenergic blocking agents along with either oral or intravenous calcium antagonists should be monitored for possible atrioventricular conduction disturbances, <span class="product-label-link" type="condition" conceptid="439846" conceptname="Left heart failure">left ventricular failure</span> and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. In patients with impaired cardiac function, simultaneous use should be avoided altogether. The concomitant use of betaadrenergic blocking agents with digitalis and calcium antagonists may have additive effects on prolonging atrioventricular conduction time.</p>
<p>Phenothiazine-related compounds and beta-adrenergic blocking agents may have additive hypotensive effects due to the inhibition of each other's metabolism.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0fbbc654-91f3-42b0-b996-5118d4c41391"></a><a name="section-7.4"></a><p></p>
<h2>Risk of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span>:</h2>
<p class="First">While taking beta-blockers, patients with a history of severe <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a2a0ee41-5b84-4b9b-b4be-565239e6172e"></a><a name="section-7.5"></a><p></p>
<h2>Animal Studies: </h2>
<p class="First">No adverse ocular effects were observed in rabbits administered levobunolol hydrochloride topically in studies lasting one year in concentrations up to 10 times the human dose concentration.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_c8fce329-b4b9-46e9-8928-d4def027342c"></a><a name="section-7.6"></a><p></p>
<h2>Carcinogenesis, mutagenesis, impairment of fertility</h2>
<p class="First">In a lifetime oral study in mice, there were statistically significant (p &lt; 0.05) increases in the incidence of benign leiomyomas in female mice at 200 mg/kg/day (14,000 times the recommended human dose for <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>), but not at 12 or 50 mg/kg/day (850 and 3,500 times the human dose). In a two-year oral study of levobunolol hydrochloride in rats, there was a statistically significant (p &lt; 0.05) increase in the incidence of benign <span class="product-label-link" type="condition" conceptid="4101758" conceptname="Hepatocellular carcinoma">hepatomas</span> in male rats administered 12,800 times the recommended human dose for <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>. Similar differences were not observed in rats administered oral doses equivalent to 350 times to 2,000 times the recommended human dose for <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>.</p>
<p>Levobunolol did not show evidence of mutagenic activity in a battery of microbiological and mammalian <span class="Italics">in vitro </span>and <span class="Italics">in vivo </span>assays.</p>
<p>Reproduction and fertility studies in rats showed no adverse effect on male or female fertility at doses up to 1,800 times the recommended human dose for <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d068245b-5830-4ff0-a8be-1c4e42c8ceab"></a><a name="section-7.7"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ba749556-ba7f-47f5-93fb-9d5c87f76472"></a><a name="section-7.7.1"></a><p></p>
<h3><span class="Bold">Category C:</span></h3>
<p class="First">Fetotoxicity (as evidenced by a greater number of resorption sites) has been observed in rabbits when doses of levobunolol hydrochloride equivalent to 200 and 700 times the recommended dose for the treatment of <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> were given. No fetotoxic effects have been observed in similar studies with rats at up to 1,800 times the human dose for <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>. Teratogenic studies with levobunolol in rats at doses up to 25 mg/kg/day (1,800 times the recommended human dose for <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>) showed no evidence of <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformations</span>. There were no adverse effects on post-natal development of offspring. It appears when results from studies using rats and studies with other beta-adrenergic blockers are examined, that the rabbit may be a particularly sensitive species. There are no adequate and well-controlled studies in pregnant women. Levobunolol hydrochloride ophthalmic solution should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_53fe509c-142e-467d-bcec-bd955d0060c9"></a><a name="section-7.8"></a><p></p>
<h2>Nursing mothers</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Systemic beta-blockers and topical timolol maleate are known to be excreted in human milk. Caution should be exercised when Levobunolol hydrochloride ophthalmic solution is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_68ceb551-ee14-4084-b346-52a3398cdeff"></a><a name="section-7.9"></a><p></p>
<h2>Pediatric use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_9d384cbb-a326-408f-9835-759e8274d5a7"></a><a name="section-7.10"></a><p></p>
<h2>Geriatric use</h2>
<p class="First">No overall differences in safety or effectiveness have been observed between elderly and younger patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_990cb4d3-b09e-4219-aa6f-c3cd14dd31e0"></a><a name="section-8"></a><p></p>
<h1>Adverse Reactions</h1>
<p class="First">In clinical trials the use of levobunolol hydrochloride has been associated with transient ocular burning and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span> in up to 1 in 3 patients, and with <span class="product-label-link" type="condition" conceptid="374347" conceptname="Blepharoconjunctivitis">blepharoconjunctivitis</span> in up to 1 in 20 patients. Decreases in heart rate and blood pressure have been reported (see <a href="#i4i_contraindications_id_16ca764a-4c96-4606-a284-b3a9f2cfb67d">CONTRAINDICATIONS</a> and <a href="#i4i_warnings_id_396d4f4b-40b7-44c3-8d75-e5ae839028f3">WARNINGS</a>).</p>
<p>The following adverse effects have been reported rarely with the use of levobunolol: <span class="product-label-link" type="condition" conceptid="434926" conceptname="Iridocyclitis">iridocyclitis</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, transient <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>.</p>
<p>Decreased corneal sensitivity has been noted in a small number of patients. Although levobunolol has minimal membrane-stabilizing activity, there remains a possibility of decreased corneal sensitivity after prolonged use.</p>
<p>The following additional adverse reactions have been reported either with levobunolol or ophthalmic use of other beta-adrenergic receptor blocking agents: <span class="Bold">BODY AS A WHOLE</span>: <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>. <span class="Bold">CARDIOVASCULAR: </span><span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>, cerebral vascular <span class="product-label-link" type="condition" conceptid="440279" conceptname="Accident">accident</span>, <span class="product-label-link" type="condition" conceptid="374384" conceptname="Cerebral ischemia">cerebral ischemia</span>, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>. <span class="Bold">DIGESTIVE: </span><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. <span class="Bold">PSYCHIATRIC: </span><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, increase in signs and symptoms of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>. <span class="Bold">SKIN: </span><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>, including localized and generalized <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span>. <span class="Bold">RESPIRATORY: </span><span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span> (predominantly in patients with pre-existing bronchospastic disease), <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>. <span class="Bold">UROGENITAL: </span><span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Impotence</span>. <span class="Bold">ENDOCRINE: </span>Masked symptoms of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> in insulin-dependent diabetics (see <a href="#i4i_warnings_id_396d4f4b-40b7-44c3-8d75-e5ae839028f3">WARNINGS</a>). <span class="Bold">SPECIAL SENSES: </span>Signs and symptoms of <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span>, <span class="product-label-link" type="condition" conceptid="373194" conceptname="Paralytic ptosis">blepharoptosis</span>, <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span> including refractive changes (due to withdrawal of miotic therapy in some cases), <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="373194" conceptname="Paralytic ptosis">ptosis</span>.</p>
<p>Other reactions associated with the oral use of non-selective adrenergic receptor blocking agents should be considered potential effects with ophthalmic use of these agents.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_aaa15869-04b0-4793-b903-3f1fe8eb84a1"></a><a name="section-9"></a><p></p>
<h1>Overdosage</h1>
<p class="First">No data are available regarding overdosage in humans. Should accidental ocular overdosage occur, flush eye(s) with water or normal saline. If accidentally ingested, efforts to decrease further absorption may be appropriate (gastric lavage).</p>
<p>The most common signs and symptoms to be expected with overdosage with administration of a systemic beta-adrenergic blocking agent are symptomatic <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, and acute <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>. Should these symptoms occur, discontinue levobunolol therapy and initiate appropriate supportive therapy. The following supportive measures should be considered:</p>
<p>1. Symptomatic <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>: Use atropine sulfate intravenously in a dosage of 0.25 mg to 2 mg to induce vagal blockade. If <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> persists, intravenous isoproterenol hydrochloride should be administered cautiously. In refractory cases the use of a transvenous cardiac pacemaker should be considered.</p>
<p>2. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>: Use sympathomimetic pressor drug therapy, such as dopamine, dobutamine or levarterenol. In refractory cases, the use of glucagon hydrochloride may be useful.</p>
<p>3. <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span>: Use isoproterenol hydrochloride. Additional therapy with aminophylline may be considered.</p>
<p>4. Acute <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>: Conventional therapy with digitalis, diuretics and oxygen should be instituted immediately. In refractory cases the use of intravenous aminophylline is suggested. This may be followed, if necessary, by glucagon hydrochloride which may be useful.</p>
<p>5. <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">Heart block</span> (second or third degree): Use isoproterenol hydrochloride or a transvenous cardiac pacemaker.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_fda10996-9e2b-45c8-9908-d65140c6b2c4"></a><a name="section-10"></a><p></p>
<h1>Dosage and Administration</h1>
<p class="First">The recommended starting dose is one to two drops of levobunolol hydrochloride ophthalmic solution 0.5% in the affected eye(s) once a day. Typical dosing with levobunolol hydrochloride ophthalmic solution 0.25% is one to two drops twice daily. In patients with more severe or uncontrolled <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, levobunolol hydrochloride ophthalmic solution 0.5% can be administered b.i.d. As with any new medication, carefully monitoring of patients is advised.</p>
<p>Dosages above one drop of levobunolol hydrochloride ophthalmic solution 0.5% b.i.d. are not generally more effective. If the patient's IOP is not at a satisfactory level on this regimen, concomitant therapy with dipivefrin and/or epinephrine, and/or pilocarpine and other miotics, and/or systemically administered carbonic anhydrase inhibitors, such as acetazolamide, can be instituted. Patients should not typically use two or more topical ophthalmic beta-adrenergic blocking agents simultaneously.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_e80d374a-8bff-48e6-85a3-68974a1fe06d"></a><a name="section-11"></a><p></p>
<h1>How Supplied</h1>
<p class="First">Levobunolol hydrochloride ophthalmic solution USP, is supplied in a plastic bottle with a controlled drop tip in the following sizes:</p>
<p><span class="Bold">0.25% </span>5 mL bottles - Prod. No. 28407 </p>
<p>             10 mL bottles - Prod. No. 28409 </p>
<p><span class="Bold">0.5% </span>5 mL bottles - Prod. No. 28507</p>
<p>            10 mL bottles - Prod. No. 28509</p>
<p>            15 mL bottles - Prod. No. 28511</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cdae2881-7279-4457-baad-9d2018a76967"></a><a name="section-12"></a><p></p>
<h1>Storage</h1>
<p class="First">Store between 15°-25°C (59°-77°F). Protect from light. Replace cap immediately after use.</p>
<p><span class="Bold">DO NOT USE IF IMPRINTED NECKBAND IS NOT INTACT</span></p>
<p><span class="Bold">KEEP OUT OF REACH OF CHILDREN</span></p>
<p>Revised October 2007</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5449f9e2-4265-454d-bfe3-8f2861d2532c"></a><a name="section-13"></a><p></p>
<p class="First"><span class="Bold">Bausch &amp; Lomb Incorporated</span></p>
<p>Tampa, Florida 33637 </p>
<p>©Bausch &amp; Lomb Incorporated</p>
<p>9117401 <span class="Bold">(Folded)</span></p>
<p>9117501 <span class="Bold">(Flat)</span></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_606823ff-f515-4cc1-84b4-514738e7ddb2"></a><a name="section-14"></a><p></p>
<h1>Principal Display Panel</h1>
<div class="Figure">
<a name="id766"></a><img alt="0.25 10 mL carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5ab1efbe-530b-4787-b40a-c7dbf18161e1&amp;name=371d1b92-5189-42bb-806f-6021eef34655-02.jpg">
</div>
<p class="First">NDC 24208-545-10</p>
<p>Bausch &amp; Lomb <br>Levobunolol Hydrochloride Ophthmalic Solution USP, <br>0.25% (Sterile) </p>
<p>Rx only</p>
<p>[icon-eye] <br>[icon- 0.25%]<br>[icon- solution] <br>[icon- 10 mL]</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_51caac6c-a4f8-4485-8ffc-60bb2ca7228c"></a><a name="section-15"></a><p></p>
<h1>Principal Dipslay Panel</h1>
<div class="Figure">
<a name="id789"></a><img alt="0.5 10 mL carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5ab1efbe-530b-4787-b40a-c7dbf18161e1&amp;name=371d1b92-5189-42bb-806f-6021eef34655-03.jpg">
</div>
<p class="First">NDC 24208-505-10</p>
<p>Bausch &amp; Lomb <br>Levobunolol Hydrochloride Ophthmalic Solution USP, <br>0.5% (Sterile)</p>
<p>Rx only </p>
<p>[icon-eye] <br>[icon- 0.5%] <br>[icon- solution] <br>[icon- 10 mL]</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LEVOBUNOLOL HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">levobunolol hydrochloride solution/ drops</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:24208-505</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>LEVOBUNOLOL HYDROCHLORIDE</strong> (LEVOBUNOLOL) </td>
<td class="formItem">LEVOBUNOLOL HYDROCHLORIDE</td>
<td class="formItem">5 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BENZALKONIUM CHLORIDE</strong></td>
<td class="formItem">0.04 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM PHOSPHATE, DIBASIC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>EDETATE DISODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POTASSIUM PHOSPHATE, MONOBASIC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYVINYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM METABISULFITE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:24208-505-05</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">5 mL in 1 BOTTLE, DROPPER; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:24208-505-10</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">10 mL in 1 BOTTLE, DROPPER; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:24208-505-15</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem"></td>
<td class="formItem">15 mL in 1 BOTTLE, DROPPER; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA074326</td>
<td class="formItem">03/04/1994</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LEVOBUNOLOL HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">levobunolol hydrochloride solution/ drops</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:24208-545</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>LEVOBUNOLOL HYDROCHLORIDE</strong> (LEVOBUNOLOL) </td>
<td class="formItem">LEVOBUNOLOL HYDROCHLORIDE</td>
<td class="formItem">2.5 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BENZALKONIUM CHLORIDE</strong></td>
<td class="formItem">0.04 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM PHOSPHATE, DIBASIC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>EDETATE DISODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POTASSIUM PHOSPHATE, MONOBASIC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYVINYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM METABISULFITE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:24208-545-05</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">5 mL in 1 BOTTLE, DROPPER; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:24208-545-10</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">10 mL in 1 BOTTLE, DROPPER; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA074307</td>
<td class="formItem">03/04/1994</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Bausch &amp; Lomb Incorporated
							(196603781)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Bausch &amp; Lomb Incorporated</td>
<td class="formItem"></td>
<td class="formItem">079587625</td>
<td class="formItem">MANUFACTURE(24208-505, 24208-545)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Medichem S.A.</td>
<td class="formItem"></td>
<td class="formItem">464043381</td>
<td class="formItem">API MANUFACTURE(24208-505, 24208-545)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Medichem Manufacturing (Malta) Ltd.</td>
<td class="formItem"></td>
<td class="formItem">565453425</td>
<td class="formItem">API MANUFACTURE(24208-505, 24208-545)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Sifavitor srl</td>
<td class="formItem"></td>
<td class="formItem">338490579</td>
<td class="formItem">API MANUFACTURE(24208-505)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 4/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>bf286f6f-88a3-4630-b55b-2b66ff66a78c</div>
<div>Set id: 5ab1efbe-530b-4787-b40a-c7dbf18161e1</div>
<div>Version: 7</div>
<div>Effective Time: 20130403</div>
</div>
</div> <div class="DistributorName">Bausch &amp; Lomb Incorporated</div></p>
</body></html>
